Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and May Elicit NS1-Specific Antibody Responses in Vaccinated Individuals

0540111 - BC 2021 RIV CH eng J - Článek v odborném periodiku
Salát, J. - Mikulášek, K. - Larralde, O. - Formanová, P.P. - Chrdle, A. - Haviernik, J. - Elsterová, Jana - Teislerova, D. - Palus, Martin - Eyer, Luděk - Zdráhal, Z. - Petrik, J. - Růžek, Daniel
Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and May Elicit NS1-Specific Antibody Responses in Vaccinated Individuals.
Vaccines. Roč. 8, č. 1 (2020), č. článku 81. E-ISSN 2076-393X
Grant CEP: GA ČR(CZ) GA20-14325S
Institucionální podpora: RVO:60077344
Klíčová slova: japanese encephalitis * endothelial-cells * yellow-fever * ns1 * immunization * protection * mice * tick-borne encephalitis * vaccination * ns1 * vaccine * flavivirus
Obor OECD: Microbiology
Impakt faktor: 4.422, rok: 2020
Způsob publikování: Open access
https://www.mdpi.com/2076-393X/8/1/81

Vaccination against tick-borne encephalitis (TBE) is based on the use of formalin-inactivated, culture-derived whole-virus vaccines. Immune response following vaccination is primarily directed to the viral envelope (E) protein, the major viral surface antigen. In Europe, two TBE vaccines are available in adult and pediatric formulations, namely FSME-IMMUN (R) (Pfizer) and Encepur((R)) (GlaxoSmithKline). Herein, we analyzed the content of these vaccines using mass spectrometry (MS). The MS analysis revealed that the Encepur vaccine contains not only proteins of the whole virus particle, but also viral non-structural protein 1 (NS1). MS analysis of the FSME-IMMUN vaccine failed due to the high content of human serum albumin used as a stabilizer in the vaccine. However, the presence of NS1 in FSME-IMMUN was confirmed by immunization of mice with six doses of this vaccine, which led to a robust anti-NS1 antibody response. NS1-specific Western blot analysis also detected anti-NS1 antibodies in sera of humans who received multiple doses of either of these two vaccines, however, most vaccinees who received <= 3 doses were negative for NS1-specific antibodies. The contribution of NS1-specific antibodies to protection against TBE was demonstrated by immunization of mice with purified NS1 antigen, which led to a significant (p < 0.01) prolongation of the mean survival time after lethal virus challenge. This indicates that stimulation of anti-NS1 immunity by the TBE vaccines may increase their protective effect.
Trvalý link: http://hdl.handle.net/11104/0317776